Meeting
2021 ASCO Annual Meeting
A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
Presenter
Yunpeng Yang, MD, PhD
Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04054531
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9060)
DOI
10.1200/JCO.2021.39.15_suppl.9060
Abstract #
9060
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.
Speaker: Sawsan Rashdan, MD
Videos & Slides
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2 multicenter, randomized, open-label study in China.
Speaker: Jian Li, D.Phil